Class: Bisphosphonate IFU: Prevention and treatment of postmenopausal osteoporosis and glucocorticoid induced osteoporosis (men & women). Treatment to increase bone mass in men with osteoporosis. Treatment of Pagets disease of bone.
Class: Progestin & Estrogen IFU: Moderate acne vulgaris in females at or older than 15 years of age, who have no known contraindications to oral contraceptive therapy, desire contraception, have achieved menarche, and are unresponsive to topical anti-acne medications.
Class: Type II 5a- reductase inhibitor IFU: BPH, to improve symptoms and reduce risks of acute urinary retention and need for prostate surgery. To reduce risk of symptomatic progression of BPH, with doxazosin
Class: Type I and II 5a- reductase inhibitor (cGMP-specific) IFU: BPH, as monotherapy to improve symptoms and reduce risks of acute urinary retention and need for prostate surgery, or in combination with tamsulosin
Class: Sympathomimetic IFU: Short-term monotherapy as adjunct. In management of exogenous obesity in patients with initial body mass at or above 30kg/m 2, or at or above 27kg/m 2 in presence of other risk factors